Michelle Kinder, PhD
Michelle Kinder, PhD, is an immunologist whose research has primarily focused on how to harness the immune system to fight cancer. She received her Ph.D. in Immunology at University of Pennsylvania and completed a postdoctoral fellowship at Washington University in St. Louis. She has worked in different positions within the pharmaceutical industry over the past 10 years including as a postdoctoral fellow, a scientist in antibody effector function research, leading an immuno-oncology discovery and translational laboratory and as a clinical biomarker lead. Currently, Dr. Kinder is a Scientific Director for Immuno-Oncology in US Medical Affairs at Incyte. She has a passion for career development and is the co-founder and writer for www.womeninpharmacareers.com.
Adam M. Koppel, MD, PhD
Adam M. Koppel, MD, PhD, rejoined Bain Capital in 2016 as Managing Director of Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003 where he worked as a leader within the healthcare sector until 2014. From 2014 to 2016, Dr. Koppel was EVP of Corporate Development and Chief Strategy Officer at Biogen. Prior to initially joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey & Co in New Jersey where he served a variety of healthcare companies.
Dr. Koppel received an MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an AB and AM in History and Science.
Fiona A. Mack, PhD
As Head of JLABS @ TMC, Fiona A. Mack, PhD, is responsible for external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence, educational programming and P&L. In this role, she catalyzes and supports the translation of science and technology into valuable solutions for patients and consumers across the pharmaceutical, medical device, consumer, and healthtech sectors.
Prior to joining JLABS, Dr. Mack was Senior Director of External Innovation at Ipsen, supporting the expansion of the Rare Disease and Neuroscience portfolios. Before joining Ipsen, she was a Director of External Innovation Oncology Discovery at Roche. While at Roche, Dr. Mack led cross-functional teams to identify and evaluate opportunities based on their scientific merit and strategic alignment with oncology/immuno-oncology early discovery and clinical development pipelines. Notable activities include the acquisition of Tensha Therapeutics, Tusk Therapeutics and Ignyta, in addition to early discovery academic collaborations.
Dr. Mack began her career in industry as a Senior Research Scientist at Wyeth Oncology and eventually took on a senior leadership role when the company was acquired by Pfizer. She was able to complement internal early drug discovery expertise with external innovation as a program leader for pipeline projects. She also led external collaborations to support IND-enabling studies for anti-sense therapeutics, bi-specific immunotherapies and antibody drug conjugates.
Dr. Mack earned her Ph.D. in Cell and Molecular Biology from the University of Pennsylvania and her undergraduate degree in Biology from Cornell University. Her innovative work has been published in high impact journals and she also has several granted patents.